Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) in Indonesian Infants
NCT04071379Phase 3Completed
- Sponsor
- Bio Farma
- Start
- Oct 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of diphtheria, tetanus, pertussis (whole cell), hepatitis B and haemophilus influenzae type b vaccine in diphtheria, Tetanus, pertussis, hepatitis B (HBV), Haemophilus influenzae type b infection (Hib), sponsored by Bio Farma. Started Oct 2020; status: completed.
02
Drugs
diphtheria, tetanus, pertussis (whole cell), hepatitis B and haemophilus influenzae type b vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT04071379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071379.